Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2026)

Amneal Pharmaceuticals' Non-Current Debt history runs 10 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 19.4% year-over-year to $2.6 billion in Q1 2026; TTM through Mar 2026 was $2.6 billion, a 19.4% increase from a year earlier, with the FY2025 full-year figure at $2.6 billion, up 7.79% from the prior year.
• Non-Current Debt was little changed at $2.6 billion in Q1 2026 per AMRX's latest filing, from $2.6 billion in the prior quarter.
• Across five years, Non-Current Debt topped out at $2.7 billion in Q1 2022 and bottomed at $38.9 million in Q2 2022.
• The 5-year median for Non-Current Debt is $2.4 billion (2023), against an average of $2.2 billion.
• Across the five-year window, Non-Current Debt soared 7157.14% in 2022 and dropped 15.66% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $2.6 billion in 2022, then fell by 6.63% to $2.4 billion in 2023, then retreated by 1.41% to $2.4 billion in 2024, then rose by 7.79% to $2.6 billion in 2025, then retreated by 0.0% to $2.6 billion in 2026.
• Per Business Quant, the three latest AMRX Non-Current Debt figures stand at $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.6 billion (Q3 2025).